A5103010175- HIV/AIDS drug development and treatment
- HIV Research and Treatment
- Soil Moisture and Remote Sensing
- Synthetic Aperture Radar (SAR) Applications and Techniques
- Cancer Genomics and Diagnostics
- HIV/AIDS Research and Interventions
- Renal cell carcinoma treatment
- Renal and related cancers
- Precipitation Measurement and Analysis
- HIV-related health complications and treatments
- Pharmaceutical studies and practices
- Hepatitis C virus research
- Antibiotics Pharmacokinetics and Efficacy
- Biosimilars and Bioanalytical Methods
- Pharmacological Effects and Toxicity Studies
- Remote Sensing in Agriculture
- Pneumocystis jirovecii pneumonia detection and treatment
- Remote-Sensing Image Classification
- Cancer Cells and Metastasis
- BRCA gene mutations in cancer
- Advanced Breast Cancer Therapies
- Soil Geostatistics and Mapping
- Soil and Land Suitability Analysis
- Geophysical Methods and Applications
- Meteorological Phenomena and Simulations
Daiichi Sankyo (United States)
2020-2024
Indian Space Research Organisation
2007-2023
Gandhi Medical College & Hospital
2023
Daiichi Sankyo (Germany)
2023
Daiichi-Sankyo (South Korea)
2023
Triangle
2016-2022
Veer Narmad South Gujarat University
2016-2022
Nirma University
2017-2022
Gujarat University
2022
ViiV Healthcare (Spain)
2020
Estrogen receptor α (ESR1) mutations found in metastatic breast cancer (MBC) promote ligand-independent activation and resistance to estrogen-deprivation therapy laboratory models. The prevalence of these their potential impact on clinical outcomes has not been established.To determine the ESR1 (Y537S D538G) estrogen (ER)-positive MBC whether mutation is associated with inferior outcomes.From December 16, 2014, August 26, 2015, we analyzed cell-free DNA (cfDNA) from baseline plasma samples...
Simplified regimens for the treatment of human immunodeficiency virus type 1 (HIV-1) infection may increase patient satisfaction and facilitate adherence.In this phase 3, open-label, multicenter, noninferiority trial involving patients who had plasma HIV-1 RNA levels less than 50 copies per milliliter at least 6 months while taking standard oral antiretroviral therapy, we randomly assigned participants (1:1) to either continue their therapy or switch monthly intramuscular injections...
Long-acting injectable regimens may simplify therapy for patients with human immunodeficiency virus type 1 (HIV-1) infection.We conducted a phase 3, randomized, open-label trial in which adults HIV-1 infection who had not previously received antiretroviral were given 20 weeks of daily oral induction dolutegravir-abacavir-lamivudine. Participants an RNA level less than 50 copies per milliliter after 16 randomly assigned (1:1) to continue the current or switch cabotegravir plus rilpivirine...
Abstract Metastasis remains the main reason for renal cell carcinoma (RCC)–associated mortality. Tyrosine kinase inhibitors (TKI) impart clinical benefit most patients with RCC, but determinants of response are poorly understood. We report an integrated genomic and transcriptomic analysis metastatic clear RCC (ccRCC) treated TKI therapy identify predictors response. Patients in COMPARZ phase III trial received first-line sunitinib or pazopanib comparable efficacy. RNA-based analyses revealed...
Efficacy and safety of long-acting cabotegravir (CAB) rilpivirine (RPV) dosed intramuscularly every 4 or 8 weeks has been demonstrated in three Phase 3 trials. Here, factors associated with virologic failure at Week 48 were evaluated post hoc.
Abstract Background Previously reported post hoc multivariable analyses exploring predictors of confirmed virologic failure (CVF) with cabotegravir + rilpivirine long-acting (CAB RPV LA) were expanded to include data beyond week 48, additional covariates, and participants. Methods Pooled from 1651 participants used explore dosing regimen (every 4 or every 8 weeks), demographic, viral, pharmacokinetic covariates as potential CVF. Prior experience was accounted for using 2 populations. Two...
This study evaluated the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of milademetan, a small-molecule murine double minute-2 (MDM2) inhibitor, in patients with advanced cancers.
The European Standards Committee on Oxidative DNA Damage (ESCODD) was set up to resolve the problems associated with measurement of background levels oxidative damage (in particular 8-oxo-7,8-dihydroguanine, or 8-oxoGua) in human cells. A tendency for oxidation occur during sample preparation prior chromatography has been recognized as source a very substantial artefact. To assess success attempts eliminate artefact, ESCODD distributed its members standard samples pig liver and HeLa cells...
Abacavir sulfate/lamivudine (ABC/3TC) and tenofovir DF/emtricitabine (TDF/FTC) are widely used nucleoside reverse transcriptase inhibitors for initial HIV-1 treatment. This is the first completed, randomized clinical trial to directly compare efficacy, safety, tolerability of these agents, each in combination with lopinavir/ritonavir antiretroviral-naive patients.Six hundred eighty-eight antiretroviral-naive, HIV-1-infected patients were this double-blind, placebo-matched, multicenter,...
The sensitivity of synthetic aperture radar (SAR) backscatter to soil moisture has been adequately established. However, monitoring over large agricultural areas is still difficult because SAR also sensitive other target properties like surface roughness, crop cover, and texture (soil type), along with its strong moisture. Hence, develop a methodology for large-area estimation using SAR, it necessary incorporate the effects in retrieval model. In this paper, area developed pair low-...
The current analysis was performed to evaluate the impact of PIK3CA hotspot mutations on everolimus efficacy in BOLERO-2 participants, using cell-free DNA (cfDNA) from plasma samples collected at time patient randomisation. H1047R, E545K, and E542K plasma-derived cfDNA were analysed by droplet digital PCR (ddPCR). Median PFS estimated for subgroups defined each treatment arm. Among 550 patients included analysis, median vs placebo arms similar with tumours that had wild-type or mutant...
Long-acting (LA) injectable regimens are a potential therapeutic option in people living with HIV-1.ATLAS (NCT02951052) and FLAIR (NCT02938520) were 2 randomized, open-label, multicenter, multinational phase 3 studies.Adult participants virologic suppression (plasma HIV-1 RNA <50 copies/mL) randomized (1:1) to continue their current antiretroviral regimen (CAR) or switch the long-acting of cabotegravir (CAB) rilpivirine (RPV). In LA arm, initially received oral CAB + RPV once-daily for 4...
Healthy subjects received dolutegravir at 50 mg in a single-dose crossover study while they were the fasted state or with low-, moderate-, high-fat meals. Food increased exposure and reduced rate of absorption. The area under concentration-time curve from 0 h to infinity (AUC(0-∞)) by 33%, 41%, 66% when administered meals, respectively, compared fasting. This increase is not anticipated impact clinical safety, therefore can be taken without food regard fat content.
MethodsS/GSK1349572 is an unboosted, once-daily, next-generation HIV integrase inhibitor. In the first study, 16 subjects received four single-dose treatments: (i) S/GSK1349572 50 mg; (ii) mg with a multivitamin (MVI; One A Day Maximum); (iii) liquid antacid (Maalox Advanced Maximum Strength); and (iv) 2 h before antacid. second 12 single dose of alone on day 5 omeprazole.
Cabotegravir (GSK1265744) is an integrase strand transfer inhibitor in development as a long-acting (LA) intramuscular injectable suspension for HIV-1 pre-exposure prophylaxis (PrEP).We report participant outcomes from the phase IIa ECLAIR study related to tolerability, acceptability, and satisfaction of cabotegravir LA.The (ClinicalTrials.gov identifier, NCT02076178) was randomized, placebo-controlled healthy men not at high risk acquiring HIV-1. Participants were randomized (5:1)...